Ethocle Reports has published its latest Market Research Report on Hyperglycemia - Pipeline Review, H2 2016. Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. Browse market data tables and figures.

1. Hyperglycemia- Pipeline Review,H22016
Ethocle Reportshaspublished its latest MarketResearch Reporton Hyperglycemia- Pipeline Review,H2
2016. Procurestrategically importantcompetitorinformation,analysis,and insightsto formulate
effectiveR&D strategies. Browsemarketdata tablesand figures.
PublishedOn:14-Dec-2016 | Pages:44
Summary
Global MarketsDirect's latestPharmaceutical andHealthcare disease pipeline guide Hyperglycemia –
Pipeline Review,H22016, providesanoverview of the Hyperglycemia(MetabolicDisorders)pipeline
landscape.
Hyperglycemiaisa conditionthatoccurswhenbloodglucose levelsgettoohigh.Several factorscan
contribute tohyperglycemia,includingfoodandphysical activitychoices,illness,non-diabetes
medications,ornottakingenoughglucose-loweringmedication.Symptomsinclude frequenturination,
blurredvision,fatigue headache,nausea andvomiting,drymouth,comaandconfusion.Treatment
includesanti-hyperglycemictherapyandinsulintherapy.
Click here to find out more about this report?
Report Highlights
Global MarketsDirect's Pharmaceutical andHealthcare latestpipelineguideHyperglycemia –Pipeline
Review,H22016, providescomprehensiveinformationonthe therapeuticsunderdevelopmentfor
Hyperglycemia(MetabolicDisorders),complete withanalysisbystage of development,drugtarget,
mechanismof action(MoA),route of administration(RoA) andmolecule type.The guide coversthe
descriptive pharmacological actionof the therapeutics,itscompleteresearchanddevelopmenthistory
and latestnewsandpressreleases.
The Hyperglycemia(MetabolicDisorders) pipeline guidealsoreviewsof keyplayersinvolvedin
therapeuticdevelopmentforHyperglycemiaandfeaturesdormantanddiscontinuedprojects.The guide
coverstherapeuticsunderDevelopmentbyCompanies/Universities/Institutes,the molecules
developedbyCompaniesinPhase IandPreclinical stagesare 1and 4 respectively.Similarly,the

2. UniversitiesportfolioinPreclinical andDiscoverystagescomprises6and1 molecules,
respectively.Hyperglycemia.
Hyperglycemia(MetabolicDisorders)pipelineguide helpsinidentifyingandtrackingemergingplayersin
the marketand theirportfolios,enhancesdecisionmakingcapabilitiesandhelpstocreate effective
counterstrategiestogaincompetitiveadvantage.The guide isbuiltusingdataandinformationsourced
fromGlobal Markets Direct’sproprietarydatabases,company/universitywebsites,clinical trial
registries,conferences,SECfilings,investorpresentationsandfeaturedpressreleasesfrom
company/universitysitesandindustry-specificthirdpartysources.Additionally,variousdynamic
trackingprocessesensure thatthe mostrecentdevelopmentsare capturedona real time basis.
Note:Certaincontent/ sectionsinthe pipeline guidemaybe removedoralteredbasedonthe
availabilityandrelevance of data.
Get Free Sample Report
Click here for Discounts
Scope
- The pipelineguide providesasnapshotof the global therapeuticlandscapeof Hyperglycemia
(MetabolicDisorders).
- The pipelineguide reviewspipelinetherapeuticsforHyperglycemia(MetabolicDisorders)by
companiesanduniversities/researchinstitutesbasedoninformationderivedfromcompanyand
industry-specificsources.
- The pipelineguide covers pipeline productsbasedonseveralstagesof developmentrangingfrompre-
registrationtill discoveryandundisclosedstages.
- The pipelineguide featuresdescriptivedrugprofilesforthe pipelineproductswhichcomprise, product
description,descriptive licensingandcollaborationdetails,R&Dbrief,MoA & otherdevelopmental
activities.
- The pipelineguide reviewskeycompaniesinvolvedinHyperglycemia(MetabolicDisorders)
therapeuticsandenlistsall theirmajorand minorprojects.
- The pipelineguide evaluatesHyperglycemia(MetabolicDisorders)therapeuticsbasedonmechanism
of action(MoA),drugtarget,route of administration(RoA) andmolecule type.

3. - The pipelineguide encapsulatesall the dormantanddiscontinuedpipeline projects.
- The pipelineguide reviewslatestnewsrelatedtopipelinetherapeuticsforHyperglycemia(Metabolic
Disorders)
Reasons to buy
- Procure strategicallyimportantcompetitorinformation,analysis,andinsightstoformulateeffective
R&D strategies.
- Recognize emergingplayerswithpotentiallystrongproductportfolioandcreate effective counter-
strategiestogaincompetitiveadvantage.
- Findandrecognize significantandvariedtypesof therapeuticsunderdevelopmentforHyperglycemia
(MetabolicDisorders).
- Classifypotential new clientsorpartnersinthe target demographic.
- Developtactical initiativesbyunderstandingthe focusareasof leadingcompanies.
- Planmergersandacquisitionsmeritoriouslybyidentifyingkeyplayersandit’smostpromisingpipeline
therapeutics.
- Formulate corrective measuresforpipeline projectsbyunderstandingHyperglycemia(Metabolic
Disorders) pipeline depthandfocusof Indicationtherapeutics.
- Developanddesignin-licensingandout-licensingstrategiesbyidentifyingprospectivepartnerswith
the most attractive projectstoenhance andexpandbusinesspotential andscope.
- Adjustthe therapeuticportfoliobyrecognizingdiscontinuedprojectsandunderstandfromthe know-
howwhat drove themfrompipeline.
Table of Contents
List of Tables4
List of Figures4
Introduction5
Global MarketsDirect ReportCoverage 5
HyperglycemiaOverview 6

4. TherapeuticsDevelopment7
Pipeline ProductsforHyperglycemia - Overview 7
Pipeline ProductsforHyperglycemia- Comparative Analysis8
Hyperglycemia- TherapeuticsunderDevelopmentbyCompanies9
Hyperglycemia- TherapeuticsunderInvestigationbyUniversities/Institutes10
Hyperglycemia- Pipeline ProductsGlance 11
Clinical Stage Products11
Early Stage Products12
Hyperglycemia- ProductsunderDevelopmentbyCompanies13
Hyperglycemia- ProductsunderInvestigationbyUniversities/Institutes14
Hyperglycemia- CompaniesInvolvedinTherapeuticsDevelopment15
Eli LillyandCompany15
Kissei Pharmaceutical CoLtd16
Mitsubishi Tanabe PharmaCorp17
PhaseBioPharmaceuticalsInc18
Hyperglycemia- TherapeuticsAssessment19
AssessmentbyMonotherapyProducts19
AssessmentbyTarget20
AssessmentbyMechanismof Action22
AssessmentbyRoute of Administration24
AssessmentbyMolecule Type 26
Drug Profiles28
CDR-267F018 - Drug Profile 28
ProductDescription28
MechanismOf Action28

5. R&D Progress28
Drugs to InhibitABHD6for Gastrointestinal andMetabolicDisorders - DrugProfile 29
ProductDescription 29
MechanismOf Action29
R&D Progress29
FGH-10019 - Drug Profile 30
ProductDescription30
MechanismOf Action30
R&D Progress30
KR-62980 - Drug Profile 31
ProductDescription31
MechanismOf Action31
R&D Progress31
PE-0139 - Drug Profile 33
ProductDescription33
MechanismOf Action33
R&D Progress33
RecombinantPeptide toAgonizeGlucagonReceptorforHyperglycemia - Drug Profile 35
ProductDescription35
MechanismOf Action35
R&D Progress35
Small Molecule toInhibitSGLT1for Postprandial Hyperglycemia- DrugProfile 36
ProductDescription36
MechanismOf Action36
R&D Progress36

6. Small MoleculestoAntagonizePSTReceptorforDysglycemicStates - Drug Profile 37
ProductDescription37
MechanismOf Action37
R&D Progress37
Small MoleculestoInhibitDPP-IV forHyperglycemia- DrugProfile 38
ProductDescription38
MechanismOf Action38
R&D Progress38
Small MoleculestoInhibitPEPCKforType 2 DiabetesandHyperglycemia - Drug Profile 39
ProductDescription39
MechanismOf Action39
R&D Progress39
Small MoleculestoInhibitProkineticinReceptorforMetabolicDisorders - DrugProfile 40
ProductDescription40
MechanismOf Action40
R&D Progress40
SyntheticPeptidestoAntagonize GlucagonReceptorforHyperglycemiaandType 2 Diabetes - Drug
Profile 41
ProductDescription41
MechanismOf Action41
R&D Progress41
Hyperglycemia- DormantProjects42
Appendix 43
Methodology43
Coverage 43
SecondaryResearch43

7. PrimaryResearch43
ExpertPanel Validation43
Contact Us 43
Disclaimer44